Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Next Previous
Trial Profile

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Bladder cancer; Carcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Cutaneous T-cell lymphoma; Glioma; Gynaecological cancer; Head and neck cancer; Leukaemia; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Mesothelioma; Non-Hodgkin's lymphoma; Oropharyngeal cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer; Renal cell carcinoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 06 Mar 2024 Planned End Date changed from 30 Jun 2018 to 5 Mar 2025.
    • 14 Aug 2020 Results published in the Clinical Cancer Research
    • 18 Apr 2019 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top